Abivax Shares Climb 4.74% to €110.50 Following $45M Fundraising
The French biotech continues its ascent this Wednesday morning. The stock is up 4.74% at €110.50, after closing at €105.50 the previous day. The increase follows the announcement of the repurchase of royalty certificates and the raising of $45 million in ADS.
Breaking Through the Upper Bollinger Band
Abivax (FR0012333284) has surpassed its technical resistance at €109.40, previously tested in mid-April following Oddo BHF's target upgrade. The price is now above the upper Bollinger band set at €109.15, indicating an overbought condition. The RSI, at 57, remains in the neutral zone, suggesting that the buying pressure is not yet at an extreme level. The 50-day moving average is at €100.91, about 9% below the current price. The annual performance exceeds 1,650%, and the stock has gained 15.65% over the week. This movement extends the reaction to the repurchase of royalty certificates announced on Tuesday.
Financial Visibility Until Q4 2027 and Clinical Schedule
During the third quarter 2025 report, the company indicated it had the means to fund its cash needs until the fourth quarter of 2027. This autonomy was further strengthened by the recent ADS operation, which raised €38.5 million. Highlights of this publication included the progress of phase 3 trials of Obefazimod in ulcerative colitis. The Digestive Disease Week congress, held in Chicago until May 5, featured nine scientific presentations on the molecule. The company also reiterated the inherent risks associated with clinical development and decisions by regulatory authorities (FDA, EMA). The CAC 40 is up 1.56% at 8,187.98 points during the session. The next financial calendar event is the release of the first quarter 2026 results, scheduled for June 1.
